Protalix BioTherapeutics, Inc. (NYSE American: PLX) announced its financial results for the fiscal year ended December 31, 2025, along with a business and clinical update. The company reported revenues from selling goods of $51.8 million, a slight decrease from $53.0 million in 2024. This decline was primarily due to a $6.8 million drop in sales to Chiesi, offset by increased sales to Pfizer and Fiocruz. The company also reported a net loss of approximately $6.6 million for the year, compared to a net income of $2.9 million in 2024. Despite these challenges, Protalix highlighted significant achievements, including the European Commission's approval of a new dosing regimen for Elfabrio, which is expected to enhance patient compliance and reduce treatment burden. This approval triggered a $25 million milestone payment from Chiesi, bolstering the company's cash position to approximately $50 million by April 2026. Looking ahead, Protalix anticipates total revenues in 2026 to range from $78 million to $83 million, including the milestone payment. The company is actively enrolling patients in the Phase 2 clinical trial of PRX-115, which aims to address uncontrolled gout, and is focusing on rare renal diseases with its PRX-119 program. Protalix remains committed to driving profitable growth and expanding its pipeline through innovation and strategic partnerships.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.